tetano
Editor, Senior Moderator
Int J Infect Dis. 2019 Mar 26. pii: S1201-9712(19)30155-9. doi: 10.1016/j.ijid.2019.03.026. [Epub ahead of print]
[h=1]Immunogenicity of aIIV3, MF59-Adjuvanted Seasonal Trivalent Influenza Vaccine, in Older Adults ≥65 Years of Age: Meta-Analysis of Cumulative Clinical Experience.[/h] Nicolay U[SUP]1[/SUP], Heijnen E[SUP]2[/SUP], Nacci P[SUP]3[/SUP], Patriarca PA[SUP]4[/SUP], Leav B[SUP]5[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]OBJECTIVE:[/h] Compare the immunogenicity of MF59-adjuvanted trivalent inactivated influenza vaccine (aIIV3; Fluad?) versus conventional trivalent inactivated influenza vaccine (IIV3) in an integrated dataset using a meta-analysis.
[h=4]METHODS:[/h] In a meta-analysis, the immunogenicity of aIIV3 in subjects ≥65 years of age was compared with IIV3 immunogenicity using hemagglutination inhibition assay results from 23 phase I through III randomized controlled trials, including 16 first-dose vaccination studies and 7 revaccination studies assessing immunogenicity after second or third annual vaccination.
[h=4]RESULTS:[/h] The full analysis set consisted of 11,105 subjects (5869 aIIV3 and 5236 IIV3). In the revaccination studies, 822 individuals received 2 consecutive annual influenza vaccinations (492 aIIV3 and 330 IIV3), and 237 received 3 (150 aIIV3 and 87 IIV3). Overall, across all strains, the meta-analyzed point estimates for seroconversion (SC) and geometric mean titer (GMT) ratio were significantly higher for aIIV3 versus IIV3. The meta-analyzed percent differences in SC with corresponding 95% confidence intervals (CI) for A/H1N1, A/H3N2, and B strain were 9.5% (5.2-13.9), 10.5% (6.6-14.5), and 12.7% (8.6-16.8), respectively. The meta-analyzed GMT ratios with corresponding 95% CI for A/H1N1, A/H3N2, and B strain were 1.15 (1.01-1.31), 1.30 (1.18-1.44), 1.23 (1.15-1.31). Antibody responses against heterologous influenza strains were also significantly higher with aIIV3. Revaccination studies showed continued robust immune response to aIIV3 with repeated vaccination.
[h=4]CONCLUSIONS:[/h] aIIV3 elicited a statistically significantly greater immune response compared to conventional IIV3 in older adults, increasing the breadth and duration of the immune response.
Copyright ? 2019. Published by Elsevier Ltd.
[h=4]KEYWORDS:[/h] MF59; adjuvant; elderly; immunogenicity; influenza vaccine
PMID: 30926542 DOI: 10.1016/j.ijid.2019.03.026
Free full text
[h=1]Immunogenicity of aIIV3, MF59-Adjuvanted Seasonal Trivalent Influenza Vaccine, in Older Adults ≥65 Years of Age: Meta-Analysis of Cumulative Clinical Experience.[/h] Nicolay U[SUP]1[/SUP], Heijnen E[SUP]2[/SUP], Nacci P[SUP]3[/SUP], Patriarca PA[SUP]4[/SUP], Leav B[SUP]5[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]OBJECTIVE:[/h] Compare the immunogenicity of MF59-adjuvanted trivalent inactivated influenza vaccine (aIIV3; Fluad?) versus conventional trivalent inactivated influenza vaccine (IIV3) in an integrated dataset using a meta-analysis.
[h=4]METHODS:[/h] In a meta-analysis, the immunogenicity of aIIV3 in subjects ≥65 years of age was compared with IIV3 immunogenicity using hemagglutination inhibition assay results from 23 phase I through III randomized controlled trials, including 16 first-dose vaccination studies and 7 revaccination studies assessing immunogenicity after second or third annual vaccination.
[h=4]RESULTS:[/h] The full analysis set consisted of 11,105 subjects (5869 aIIV3 and 5236 IIV3). In the revaccination studies, 822 individuals received 2 consecutive annual influenza vaccinations (492 aIIV3 and 330 IIV3), and 237 received 3 (150 aIIV3 and 87 IIV3). Overall, across all strains, the meta-analyzed point estimates for seroconversion (SC) and geometric mean titer (GMT) ratio were significantly higher for aIIV3 versus IIV3. The meta-analyzed percent differences in SC with corresponding 95% confidence intervals (CI) for A/H1N1, A/H3N2, and B strain were 9.5% (5.2-13.9), 10.5% (6.6-14.5), and 12.7% (8.6-16.8), respectively. The meta-analyzed GMT ratios with corresponding 95% CI for A/H1N1, A/H3N2, and B strain were 1.15 (1.01-1.31), 1.30 (1.18-1.44), 1.23 (1.15-1.31). Antibody responses against heterologous influenza strains were also significantly higher with aIIV3. Revaccination studies showed continued robust immune response to aIIV3 with repeated vaccination.
[h=4]CONCLUSIONS:[/h] aIIV3 elicited a statistically significantly greater immune response compared to conventional IIV3 in older adults, increasing the breadth and duration of the immune response.
Copyright ? 2019. Published by Elsevier Ltd.
[h=4]KEYWORDS:[/h] MF59; adjuvant; elderly; immunogenicity; influenza vaccine
PMID: 30926542 DOI: 10.1016/j.ijid.2019.03.026
Free full text